Business Wire

EIT-URBAN-MOBILITY

17.11.2022 15:39:38 CET | Business Wire | Press release

Share
Tomorrow.Mobility Shines Light on the New Driving Forces for More Liveable and Sustainable Cities

(15-17 November 2022) – Tomorrow.Mobility World Congress (TMWC) is a global event, co-organised by Fira de Barcelona and EIT Urban Mobility, in the Gran Via venue of Fira de Barcelona, focused on promoting the design and adoption of new sustainable urban mobility models and jointly organised with the Smart City Expo World Congress.

Over 80 speakers such as Kelly Larson, director of the Road Safety Programme at Bloomberg Philanthropies; Karen Vancluysen, secretary general of POLIS; Marco te Brömmelstroet, professor of Future of Urban Mobility at the University of Amsterdam; Mikael Colville-Andersen, Urban Design Expert and Maria Tsavachidis, CEO of EIT Urban Mobility, participated in the more than 20 congress and talks in Tomorrow.Mobility. EIT urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, sponsored the venue of more than 20 innovative startups. At this edition, two studies produced by EIT Urban Mobility are unveiled. FULL STUDY & Press Summary in the google drive.

The 15-minute city

The 15-minute city, is a recent concept that has taken momentum in wake of the pandemic and has been picked up by many European cities. The goal is to create a city where people could reach all their basic essential social functions like living, working, commerce, healthcare, education, and entertainment at a 15-minute by walk. In Europe, more than €1bn in cycling-related infrastructure and 2,300 kilometers of new bike lanes have been spent since the pandemic began.

Three workshops were conducted with planning practitioners from the metropolitan region of Amsterdam, Ghent, Madrid, Milan, and Munich. A key output of this study is a roadmap for the implementation of ±15-minute city strategies to ensure access all citizen’s needs, and in connection with suburb areas. 15-Minute City concepts need to be adapted to local circumstances and population groups: older people walking speed is on average around 3.5 km/h while the average speed is considered 5km/h. Hence, a 15-minute walk could represent 900-1000m at an average speed, while at a reduced speed it could be 700m.

Urban Air Mobility

Given the fast pace of innovation, air mobility is expected to become a reality in Europe within 3-5 years and air space above cities could become an extension of public space on the ground. The European UAM market size is predicted to be 4.2 billion EUR by 2030, representing a 31% global share1. To set up the scenes for an inclusive urban air mobility scheme, this first study explores the different evolution perspectives of the sector. The study collected practitioners’ insights on the development and implementation of UAM from 12 European countries from the academic, public, and private sector.

Out of the sectorial experts, 89% expect that UAM applications will play a very important or important role in improving medical transport and support in medical emergency services. 63% of questionnaire respondents think that in the logistics field, UAM will play an important or a very important role in the transport of packages in industrial spaces. By contrast, only a minority of experts see a significant role in UAM applications in e-commerce and food deliveries. In terms of challenge, when moving forward with UAM, it is essential to consult citizens and it´s important for them to feel safe, where subjective safety matters as much as objective ones. Traffic noise is the second main concern raised by the study, after safety, for the development of Urban Air Mobility for European citizens.

About EIT Urban Mobility

EIT Urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, aims to accelerate solutions and the transition towards a user-centric, integrated and truly multimodal transport system. As the leading European innovation community for urban mobility, EIT Urban Mobility works to avoid fragmentation by facilitating collaboration between cities, industry, academia, research and innovation.

1 https://www.easa.europa.eu/en/newsroom-and-events/press-releases/easa-publishes-results-first-eu-study-citizens-acceptance-urban#group-easa-downloads

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005677/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye